

Section 1: Request Summary

Country:	LIBERIA
Disease:	MALARIA
Grant number:	LBR-304-G03-M
Principal Recipient:	UNDP
Disbursement period beginning date:	1/03/05
Disbursement period end date:	31/05/05
Disbursement Request number:	2
Currency:	USD

A: CASH REQUEST

On behalf of the Principal Recipient (PR), the undersigned hereby requests the Global Fund to disburse funds under the above-referenced Grant Agreement (the "Grant Agreement") as follows, and confirms that any Conditions Precedent and/or Special Conditions for the relevant disbursement period have been met:

1. Cash amount requested from the Global Fund (amount in USD) (from Section 3. B. line 9): 3,387,041

2. Amount requested in words (in USD): Three million three hundred and eighty seven thousand and forty one US dollars

B: AUTHORIZATION

The undersigned acknowledges that funds disbursed in accordance with this request will be deposited in the bank account specified in block 9 of the face sheet of the Grant Agreement and that funds disbursed under the Grant Agreement must be used in accordance with the Grant Agreement.

Signed on behalf of the Principal Recipient:
(signature of Authorized Designated Representative)

Name: Elizabeth O.

Title: Deputy Resident Representative - Programmes

Date: 14-Apr-05

REPORT FOR FIRST QUARTER

A. Country:	Liberia
B. Disease:	Malaria
C. Grant number:	LBR-304-G03-M
D. Principal Recipient:	UNDP
E. Reporting period opening date:	1-Dec-04
F. Reporting period closing date:	28-Feb-05
G. Disbursement Request number:	2
H. Disbursement Amount in US \$	USD

Objective 1 To Improve access to adequate and efficacious drugs and treatment at the health facility and community levels including camps for displaced population

Key indicators	Baseline (if applicable)	Planned results/ targets	Actual results/ targets	Reason for programmatic deviation
Number of health workers at health facility trained in Malaria case management		93	67	The target was 93, however 67 was budgeted for the quarter
Number of health facility with no reported stock outs of anti-malaria drugs	0	--	--	Drug distribution starts in second quarter
Number of malaria cases treated with Artemisinin based derivatives	0	--	--	Treatment starts in Third quarter
Number of malaria cases treated with non-Artemisinin based derivatives	2,500,000	2,500,000		Data collation and analysis system being put in place
Number of uncomplicated Malaria cases treated within 48 hrs of onset of fever	0	150,000	--	Data collation and analysis system being put in place

Objective 2 Increase use of IPT among pregnant women

Number of pregnant women receiving correct intermittent preventive treatment (IPT)	0	--	--	Treatment starts in Third quarter
Number of health facilities implementing IPT with SP	0	--	--	Treatment starts in Third quarter

Objective 3 Increase coverage and use of personal protective measures including Insecticide Treated Materials (ITMs) and Indoor Residual Spraying

Number of Insecticide treated nets distributed	30,000	--	--	ITN will be distributed in second quarter
Number of pregnant women sleeping under insecticide treated nets	0	--	--	Sample survey will be done in fourth quarter.
Number of children under 5 sleeping under insecticide treated nets	0	--	--	Sample survey will be done in fourth quarter.

Objective 4 Increase awareness and practice of malaria control and prevention in the community

Number of schools using IEC materials on Malaria prevention and control	0	40	0	Materials are in the process of being developed. Distribution to be done in 2nd quarter
Number of teachers trained in use of Malaria IEC materials	0	750	--	Curriculum being developed and to be adopted. Training to commence from 4th quarter
Number of peer educators trained in Malaria IEC material	0	200	120	The target was 200, however 120 was budgeted for the quarter

FINANCIAL PROGRESS

Summary period budget/expenditures		Forecast	Actual	Reason for financial deviation
		93,052	102,816	PR actual expenditure is made up of GMS (\$72,087) and PEU start-up costs (\$ 30,729). The total amount forecasted for each quarter was \$72,087 (GMS) and \$ 20,965 (start-up). However the actual expenditure for start-up costs straddled across two quarters
	PR's expenditure			
		1,889,071	1,189,044	Some key activities, such as Nation wide Malaria survey were not implemented. In addition, the introduction of ACT's requires adoption by stakeholders and certain issues pertaining to side effects are being investigated, which has delayed some related activities such as development of treatment wall charts, treatment compliance cards.
	Subrecipients' expenditure			
	Total	1,982,123	1,291,860	

1 Other program results, issues, and lessons learned:

The Malaria programme has had a challenging 1st quarter of implementation especially due to the number of subrecipients and sometimes unfounded perceptions about the GF. There have been numerous consultations regarding GF implementation which have resulted in delivery of the programme. It is important to note that there were some delays in actually commencing disbursements to the subrecipients due to the issue of the issue of the first disbursement being actually received at HQ in December and the issue of the holidays. Despite those challenges, progress was made in achieving the indicators. Liberia has a very challenging context, and significant strides have been made in building partnerships and increasing coordination for prevention and control of malaria in Liberia.

2 Planned changes in program and budget based on experiences and lessons learned

There is need to revise the budget to facilitate the allocation of the funds and activities of one of the subrecipients (MERLIN) who pulled out of the program to two of the subrecipients (MERC1 and CAAP) who have the capacity and ability to implement those activities. There is also need to increase support to the National Drug Service (NDS) to ensure maximum efforts in managing risks associated with procurement and supply chain management. This need became necessary after the nationwide PSM assessment conducted as a recommendation from the GFATM/LFA assessments.

Section 3: Cash Reconciliation and Requirement

Country:	LIBERIA	
Disease:	MALARIA	
Grant number:	LBR-304-G03-M	
Principal Recipient:	UNDP	
Disbursement period beginning date:	1/12/04	
Disbursement period end date:	28/02/05	
Disbursement Request number:	2	
Currency:	USD	

A: CASH RECONCILIATION

1. Cash Balance: Beginning of disbursement period (line 5 from previous disbursement period Cash Reconciliation):	-
2. <i>Add: Sources of Cash during the disbursement period (from PR's Statement of Sources and Uses of Funds (Cash Flow Statement))</i>	
2.a. Interest received on bank account, user fees and other income received*:	-
2.b. Cash received from the Global Fund (last disbursement):	2,797,574
2.c. Total sources of cash (line 2.a. plus line 2.b.):	2,797,574
3. Total cash available for disbursement period (line 1 plus line 2.c.):	2,797,574
<i>Less: Uses of Cash during the disbursement period (from PR's Statement of Sources and Uses of Funds)</i>	
4. Total program expenditures during disbursement period (same as Section 2. B. 1. "Actual"):	1,291,858
5. Cash Balance: End of disbursement period (line 3 minus line 4):	1,505,716

B: CASH REQUIREMENT

6. Total forecasted net cash expenditures by the Principal Recipient for next disbursement period plus one additional quarter**:	4,892,757
7. Next disbursement period beginning date: <u>1-Mar-05</u> end date: <u>31-May-05</u>	
8. Subsequent quarter beginning date: <u>1-Jun-05</u> end date: <u>31-Aug-05</u>	
<i>Less: Cash Balance: End of disbursement period (line 5)</i>	
9. Cash requirement from the Global Fund for next disbursement period plus one additional quarter: (line 6 minus line 5)	3,387,041
10. Exchange Rate: (used to translate local currency into USD) <u>45 LD - 1USD</u>	

* Including income from other donors, if program supported by Global Fund is co-financed by other donors

** As supported by current budget forecasts